Results 141 to 150 of about 11,476 (293)

GLP‐1 Receptor Agonist Therapy Is Associated With Lower Risk of Lower Extremity Amputation in Adults With Type 2 Diabetes and Foot Ulcer Without Coded Peripheral Arterial Disease: A Hypothesis‐Generating Real‐World Cohort Study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To compare lower extremity amputation (LEA) risk in adults with Type 2 diabetes and diabetic foot ulcer (DFU) treated with glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) versus other glucose‐lowering therapy, and to test whether coded peripheral arterial disease (PAD) modifies this association and replicates across comparator ...
Hani Robinson   +8 more
wiley   +1 more source

DOMS: treatment or prevention?

open access: yes, 2009
peer reviewedThe evidence of benefits from eccentric contraction provides compelling rationale for their inclusion in force training and in the reeducation of various locomotor pathologies (i.e., tendinopathies or muscular imbalance). However, intense or
Leprince, Pierre   +3 more
core   +1 more source

Changes in Metabolic and Blood Pressure Outcomes With Semaglutide Across Chronic Kidney Disease Stages: A Post Hoc Analysis of the FLOW Trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To assess changes in glycated haemoglobin (HbA1c), body weight, and systolic/diastolic blood pressure (SBP/DBP) by chronic kidney disease (CKD) and albuminuria categories in a post hoc analysis of FLOW, an international, double‐blind, randomized, phase 3b clinical trial of adults with CKD and Type 2 diabetes (T2D).
Allon N. Friedman   +10 more
wiley   +1 more source

Severe Thrombocytopenia Associated With Glucagon‐Like‐1 Receptor Agonists (GPL‐1RA): A SONAR Report

open access: yes
Diabetes, Obesity and Metabolism, EarlyView.
Charles L. Bennett   +15 more
wiley   +1 more source

Real‐World Treatment Patterns and Weight Outcomes Before and After a Tirzepatide Price Increase in Over One Million Self‐Paying UK Adults With Overweight or Obesity

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Glucagon‐like peptide‐1 (GLP‐1) receptor agonist‐based medicines are highly effective treatments for overweight and obesity, but population‐scale real‐world evidence remains limited, particularly in self‐funded settings where treatment choice may be influenced by relative price.
Sophie Dix   +7 more
wiley   +1 more source

Response to “Methodological Considerations in Interpreting Renal [18F]FDG‐PET After Short‐Term Dapagliflozin Treatment”

open access: yes
Diabetes, Obesity and Metabolism, EarlyView.
Shawn Gugliandolo   +3 more
wiley   +1 more source

Autophagy Regulates Foxo1 Protein Abundance to Control Hepatic Glucose Production in Glucagon Signalling

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim During fasting, the liver undergoes coordinated metabolic adaptations to maintain systemic energy homeostasis. These adaptations are driven in part by glucagon, which promotes hepatic glucose production (HGP) and fatty acid oxidation (FAO) through mechanisms involving the transcription factor Foxo1.
Zheng Shen   +9 more
wiley   +1 more source

Role of integrin αvβ5 receptor and microglia in delayed-onset muscle soreness in mice. [PDF]

open access: yesJ Muscle Res Cell Motil
Rocha BLG   +5 more
europepmc   +1 more source

Association of GLP‐1 Receptor Agonists With Gastrointestinal and Liver Outcomes in Adults With Type 2 Diabetes: A Target Trial Emulation Study

open access: yes
Diabetes, Obesity and Metabolism, EarlyView.
Dazheng Zhang   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy